公开(公告)号：US09920116B2

公开(公告)日：2018-03-20

申请号：US15713031

申请日：2017-09-22

Applicant: Immunomedics, Inc.

Inventor： Chien-Hsing Chang ,  Hans J. Hansen ,  David M. Goldenberg

IPC: C07K16/18 ,  A61K39/395 ,  C07K16/28 ,  C07K16/24 ,  A61K31/573 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K31/473 ,  A61K31/573 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/24 ,  C07K16/248 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2851 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g., SLE), atherosclerosis, arthritis, rheumatoid arthritis, edema, sepsis, septic shock, hyperinflammatory disorder, infectious disease, inflammatory disease, immune dysregulatory disorder, GVHD, transplant rejection, atherosclerosis, asthma, a coagulopathy, myocardial ischemia, thrombosis, nephritis, inflammatory liver injury, acute pancreatitis, ischemia-reperfusion injury, stroke, cardiovascular disease, and burn.

公开(公告)号：US20180071398A1

公开(公告)日：2018-03-15

申请号：US15818225

申请日：2017-11-20

Applicant: APO-T B.V.

Inventor： Ralph Alexander Willemsen ,  Johan Renes

IPC: C07K16/28 ,  C07K16/30 ,  A61K45/06

CPC classification number: A61K47/64 ,  A61K45/06 ,  A61K47/6851 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2319/00

Abstract: Described are proteinaceous molecules comprising at least a domain that comprises an amino acid sequence that specifically binds to an MHC-peptide complex on an aberrant cell, functionally connected with a substance that induces apoptosis in aberrant cells, but not in normal cells. These proteinaceous molecules are preferably used in selectively modulating biological processes. The provided proteinaceous molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers.

公开(公告)号：US20180055883A1

公开(公告)日：2018-03-01

申请号：US15686679

申请日：2017-08-25

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WEIBE ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/47 ,  C07K16/28 ,  C07K14/74 ,  C07K16/30 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/3053 ,  C12N5/0636 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180051085A1

公开(公告)日：2018-02-22

申请号：US15803193

申请日：2017-11-03

Applicant: Immunomedics, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K38/21

CPC classification number: C07K16/2818 ,  A61K31/4745 ,  A61K38/21 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6863 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61P35/00 ,  A61P35/04 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention concerns compositions and methods of use of anti-PD-1 antibodies comprising CDR sequences corresponding to SEQ ID NO:1 to SEQ ID NO:6. Preferably the antibody is a humanized antibody comprising the variable region amino acid sequences of SEQ ID NO: 9 and SEQ ID NO:10. The antibodies are of use to treat cancer and may be administered alone or with another standard anti-cancer therapy. The methods may comprise administering the anti-PD-1 antibody or antigen-binding fragment thereof in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or other checkpoint inhibitor antibodies.

公开(公告)号：US09888673B2

公开(公告)日：2018-02-13

申请号：US14965451

申请日：2015-12-10

Applicant: Regents of the University of Minnesota

Inventor： Bernhard J. Hering ,  Christopher Burlak

IPC: A01K15/00 ,  A01K67/027 ,  C12N5/071 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K35/12 ,  A61K35/15 ,  A61K35/26 ,  A61K35/28 ,  A61K35/39 ,  C12N15/113

CPC classification number: A01K67/0275 ,  A01K2217/15 ,  A01K2227/108 ,  A01K2267/025 ,  A61K31/436 ,  A61K31/675 ,  A61K35/12 ,  A61K35/15 ,  A61K35/26 ,  A61K35/28 ,  A61K35/39 ,  A61K39/395 ,  A61K45/06 ,  C07K16/2833 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K2317/76 ,  C07K2319/30 ,  C12N5/0676 ,  C12N5/0677 ,  C12N15/113 ,  C12N2310/10 ,  C12N2310/20 ,  A61K2300/00

Abstract: Genetically modified cells, tissues, and organs for treating or preventing diseases are disclosed. Also disclosed are methods of making the genetically modified cells and non-human animals.

公开(公告)号：US20170360770A1

公开(公告)日：2017-12-21

申请号：US15669264

申请日：2017-08-04

Applicant: Immunomedics, Inc.

Inventor： Serengulam V. Govindan ,  Thomas M. Cardillo ,  David M. Goldenberg

IPC: A61K31/4745 ,  A61K31/675 ,  A61B6/00 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/513 ,  C07K16/30 ,  C07K16/28 ,  C07K16/32 ,  A61K45/06 ,  A61K31/713 ,  A61K31/7088 ,  A61K47/68 ,  A61K39/00

CPC classification number: A61K31/4745 ,  A61B6/481 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/513 ,  A61K31/675 ,  A61K31/7088 ,  A61K31/713 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6853 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/55 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3061 ,  C07K16/3092 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-HLA-DR antibody or antigen-binding antibody fragment. The immunoconjugate may be administered at a dosage of between 3 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8, 10 or 12 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. The methods and compositions are particularly useful for treating AML, ALL or multiple myeloma.

公开(公告)号：US20170326216A1

公开(公告)日：2017-11-16

申请号：US15638786

申请日：2017-06-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： ANNIKA SONNTAG ,  TONI WEINSCHENK ,  ANDREA MAHR ,  OLIVER SCHOOR ,  JENS FRITSCHE ,  HARPREET SINGH

IPC: A61K39/00

CPC classification number: C07K14/70539 ,  A61K35/17 ,  A61K38/1709 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  C07K14/7051 ,  C07K16/2833 ,  C12N5/0636 ,  C12N5/0638 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57484 ,  G01N2333/70539 ,  G06F19/20

Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.

公开(公告)号：US20170320951A1

公开(公告)日：2017-11-09

申请号：US15412452

申请日：2017-01-23

Applicant: Institut National De La Santé Et De La Recherche Médicale (INSERM) ,  Université Claude Bernard Lyon 1 ,  Ecole Normale Supérieure De Lyon ,  Centre National De La Recherche Scientifique (CNRS)

Inventor： Laurent Genestier ,  Emmanuel Bachy ,  Thierry Defrance

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  G01N33/574 ,  C12N15/115 ,  A61K38/13 ,  A61K31/713 ,  A61K39/00

CPC classification number: C07K16/2833 ,  A61K31/713 ,  A61K38/13 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/76 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/31 ,  G01N33/57407 ,  G01N2333/70539

Abstract: Methods for diagnosing and treating CD1d-restricted gamma/delta T cell lymphomas are disclosed. In particular, the present disclosure relates to a method for diagnosing a T cell lymphoma as a CD1d-restricted gamma/delta T cell lymphoma in a patient in need thereof including i) detecting the presence of CD1d restricted gamma/delta T lymphoma cells in a cell lymphoma sample obtained from the patient and ii) concluding that the T cell lymphoma is a CD1d-restricted gamma/delta T cell lymphoma when the presence of CD1d restricted gamma/delta T cells is detected in the sample. The present disclosure also relates to a method for treating a CD1d-restricted gamma/delta T cell lymphoma as diagnosed by the diagnostic method, including administering the patient with a therapeutically effective amount of a CD1d antagonist.

公开(公告)号：US09809646B2

公开(公告)日：2017-11-07

申请号：US15487747

申请日：2017-04-14

Applicant: Immunomedics, Inc.

Inventor： Chien-Hsing Chang ,  Hans J. Hansen ,  David M. Goldenberg

IPC: C07K16/18 ,  A61K39/395 ,  C07K16/24 ,  C07K16/28 ,  A61K31/573 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K31/473 ,  A61K31/573 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/24 ,  C07K16/248 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2851 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g., SLE), atherosclerosis, arthritis, rheumatoid arthritis, edema, sepsis, septic shock, hyperinflammatory disorder, infectious disease, inflammatory disease, immune dysregulatory disorder, GVHD, transplant rejection, atherosclerosis, asthma, a coagulopathy, myocardial ischemia, thrombosis, nephritis, inflammatory liver injury, acute pancreatitis, ischemia-reperfusion injury, stroke, cardiovascular disease, and burn.

公开(公告)号：US09803013B2

公开(公告)日：2017-10-31

申请号：US14250898

申请日：2014-04-11

Applicant: BioInvent International AB

Inventor： Björn Frendéus ,  Roland Carlsson ,  Ingrid Teige ,  Linda Mårtensson

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/42 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/2821 ,  C07K16/2833 ,  C07K16/4283 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/94

Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.